Convergence Empowers, Breaking Boundaries and Advancing Forward.

With the theme "Unleash Boundless Innovation, March Towards New Horizons.", the conference brought together nearly 1,000 leading experts, scholars, and industry leaders in the field of organoids from around the world. Through in-depth discussions on cutting-edge advances, clinical translation, and interdisciplinary collaboration in organoid technology, the event injected new momentum into the global development of organoid research.

Can you imagine? In computers, it is possible to "grow" organoids that are highly similar to human organs—they can simulate organ development, pathological changes, and even serve as surrogate models for real cells and tissues to undergo drug testing.

Gastric cancer cells can drive epithelial cells to autonomously secrete WNT7B via the KRAS-MAPK-SMAD2/3 axis, thereby achieving WNT self-sufficiency and completely breaking free from dependence on the tumor microenvironment. This mechanism is not only stably present in gastric cancer but also conserved in various cancers, including lung cancer, offering a novel therapeutic target for KRAS-high expression malignancies.

Have you ever wondered: every new drug we take has to be tested on animals before it hits the market? This 75-year-old "industry standard" is now on the verge of being completely overturned.